Evelo's AD Candidate Meets Phase 1b Endpoints

Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial.

According to the company, the oral drug candidate studied in 23 evaluable subjects with mild to moderate AD, also met secondary endpoints. 

Clinical differences between EDP1815 and placebo for evaluable subjects were statistically significant at day 56 in both the percentage change in EASI (62 percent difference, p=0.034) and the percentage change in IGA*BSA (71 percent difference, p=0.019). Improvements in these measures were observed as early as day 14. At day 56, 10/16 patients in the active group showed improvements in EASI score, with 4/16 patients having achieved an EASI50 clinical response, three of which achieved at least an EASI75, compared to 0/7 of patients in the placebo group.